This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Microbix Biosystems supports the FTC's proposed study of generic drug competition

( December 18, 2000, 23:31 GMT | Official Statement) -- MLex Summary: Microbix Biosystems supports the US Federal Trade Commission's proposed study of generic drug competition saying that it is imperative that the FTC investigate violations of the Hatch-Waxman Act. Microbix emphasizes that current abuse of the Hatch-Waxman Act is leading to restraint of trade, inflated healthcare prices and may lead to patient suffering which is enabling monopolists to extend their lucrative period of patent protection.See the public comment in full below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections